Secretome Therapeutics

The capital raised in this round will support operations through mid-2026 and fund key initiatives, including: Clinical Trials:?Launching two Phase 1 trials of STM-01 in HFpEF (heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with proof-of-concept data expected in Q3 2025. Manufacturing Scale-Up:?Transitioning STM-01 manufacturing to 3-dimensional bioreactor technology. Pipeline Development:?Advancing STM-21 and other preclinical programs to address inflammatory conditions. Regulatory Engagement:?Defining the regulatory pathway for STM-01 in orphan indications. Intellectual Property:?Submitting patents on next-generation cell and secretome products following the issuance of composition patents for STM-01 and STM-21.

“With these patents in place, we can confidently move our development candidates forward as we prepare to launch two Phase 1 studies for STM-01 by the end of this year,” said Vinny Jindal, President and CEO of Secretome Therapeutics. “These patents not only protect the molecular integrity of STM-01 and STM-21 but also underscore our potential to develop multiple products derived from nCPC for the treatment of a wide array of diseases driven by chronic inflammation.”

“This investment comes at a pivotal moment as we advance our lead asset, STM-01, into two Phase I clinical studies next quarter,” Vinny Jindal, president and CEO at Secretome Therapeutics, said in a statement. “The support from HEST Investments provides us with capital and aligns us with a partner who shares our vision for making groundbreaking advances in healthcare.”

#atw23